financetom
Business
financetom
/
Business
/
US business travel is back but it looks different, hotel CEOs say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US business travel is back but it looks different, hotel CEOs say
Jun 4, 2024 9:50 AM

June 4 (Reuters) - Business travel has returned to the

United States, hotel executives at a New York industry

conference said this week, as companies of all sizes are

increasingly booking trips at higher levels and prices than

before the pandemic.

Corporations are eschewing long-haul international business

travel, however, and are instead prioritizing U.S. trips. Small-

and medium-sized enterprises have led the recovery over the past

couple of years, but large corporate bookings are rising as

well.

"Business travel is back and it is on a steady rise," Hyatt

Hotels Corp ( H ) Chief Executive Officer Mark Hoplamazian said

late on Monday at the NYU International Hospitality Industry

Investment Conference.

Hoplamazian said the company's corporate accounts in April

are up 12% year-to-date and total business travel is up 6%

cumulatively year-over-year. Hyatt primarily serves larger

corporate clients.

Smaller- and medium-sized enterprises generate more repeat

business as they prioritize meeting more often and closer to

home, said Accor Chief Executive Officer Sebastien

Bazin.

Pricing for large corporate accounts is up about 5% to 8%

for the next 12 months, he said.

"Business is back but it's a different business travel mix,"

he said.

The business travel rebound is also fuelling a recovery in

group business travel, and at higher prices.

"Group is the strongest performing segment right now," said

Marriott International Chief Executive Officer Anthony

Capuano. "To get the dates, space and cities that

want, they are saying 'can I book five, six, seven years out',"

he said.

There is a tremendous level of interest by associations to

get the dates they need, said Hyatt's Hoplamazian.

"In some cases group business, this is large meetings, it's

pretty significant mid-single digit price growth, " said Hyatt's

Hoplamazian.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CACI International Awarded $273 Million Task Order
CACI International Awarded $273 Million Task Order
Sep 25, 2024
10:21 AM EDT, 09/19/2024 (MT Newswires) -- CACI International ( CACI ) said Thursday it has won a five-year order valued at as much as $273 million to continue providing intelligence expertise to the US Central Command. The company's intelligence analysts will help protect US forces from foreign adversarial threats, the company said. Price: 485.43, Change: +2.04, Percent Change: +0.42...
ReShape Lifesciences to Implement 1-for-58 Reverse Stock Split
ReShape Lifesciences to Implement 1-for-58 Reverse Stock Split
Sep 25, 2024
10:38 AM EDT, 09/19/2024 (MT Newswires) -- ReShape Lifesciences ( RSLS ) said Thursday it is implementing a one-for-58 reverse stock split of its common stock effective from Monday following the board's decision on Feb. 23. No fractional shares will be issued; instead, they will be rounded up to the nearest whole share, the company said. The company's shares were...
Holcim draws climate criticism ahead of $30 bln US spinoff
Holcim draws climate criticism ahead of $30 bln US spinoff
Sep 25, 2024
ZURICH, Sept 19 (Reuters) - Holcim's $30 billion New York spinoff of its North American business has come under fire from an environmental group that said the major cement maker was doing too little to tackle climate change. The Swiss-based company has failed to cut direct emissions from its plants or spend enough to reduce materials or energy waste, said...
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
FDA Strikes Off Vanda Pharmaceuticals' Tradipitant For Stomach Paralysis, Asks For Additional Studies
Sep 25, 2024
Thursday, the FDA declined to approve Vanda Pharmaceuticals Inc.’s  New Drug Application (NDA) of tradipitant for symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL). Gastroparesis (means paralysis of the stomach) is a condition that slows down the stomach’s ability to empty its contents. It is associated with severe nausea, vomiting, and difficulty finishing a normal meal. Also Read: What’s Going...
Copyright 2023-2026 - www.financetom.com All Rights Reserved